Los Angeles, CA / February 5, 2018 – Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TRE-515, a novel, first-in-class inhibitor of deoxycytidine kinase for the […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2018-02-05 18:57:242018-02-05 18:57:24FDA Clearance of Investigational New Drug Application for TRE-515
Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngadmin2017-01-26 19:05:452017-03-06 14:02:57Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017
25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article
Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, will attend the 2018 BIO CEO & Investor Conference on February 12-13, 2018 in New York City.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2018-02-06 06:28:242018-02-06 06:28:24Trethera to attend the BIO CEO & Investor Conference
Trethera will be presenting at the 2018 San Diego Health Impact Forum on February 7th, 2018 held at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2018-02-06 06:23:092018-02-06 06:24:14Trethera presenting at the 2018 San Diego Health Impact Forum
November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.
http://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Adminhttp://trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngAdmin2017-11-27 19:57:472017-11-27 19:58:12Trethera attending the 59th ASH Annual Meeting in Atlanta
FDA Clearance of Investigational New Drug Application for TRE-515
/in In the News, News /by AdminLos Angeles, CA / February 5, 2018 – Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TRE-515, a novel, first-in-class inhibitor of deoxycytidine kinase for the […]
Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017
/in Events, News /by adminSanta Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland. […]
UCLA Spinout Trethera Trials Novel DNA Metabolism Combination
/in In the News, News /by admin25 January 2017 SCRIP Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach. Read Article